Jingyin Pharmaceuticals Announces Completion of Phase I Clinical Trial Enrollment for Novel siRNA-Based FXI Anticoagulant SRSD107

July 11, 2024, SHANGHAI, China and SAN DIEGO, USA: Sirius Therapeutics (SHANGHAI) Co., Ltd. ("Sirius Therapeutics"), announced that the Phase I clinical trial of its self-developed small nucleic acid drug (SRSD107 injection) has recently completed dosing for all enrolled subjects. This Phase I clinical study is being conducted simultaneously in Australia and mainland China. Preliminary research data shows that SRSD107 has good safety and tolerability, as well as expected pharmacokinetic characteristics.

Dr. Peichuan Yu, Chief Medical Officer of Sirius Therapeutics, stated

Thrombosis is a blood clot that restricts blood flow within blood vessels and can occur in either arterial or venous circulation. It serves as the common pathological basis for most myocardial infarctions, ischemic strokes, and venous thromboembolism (VTE). Globally, one in four people die from diseases caused by thromboembolism.¹。

SRSD107 Injection is a double-stranded small interfering RNA (siRNA) drug independently developed by Sirius Therapeutics, with proprietary intellectual property rights. By specifically targeting the liver-directed coagulation factor XI (FXI) mRNA, it inhibits FXI protein expression, blocking the activation of the intrinsic coagulation pathway, thereby achieving anticoagulant/antithrombotic effects. Preclinical trial data show that a single subcutaneous injection of SRSD107 can achieve nearly 100% knockdown of FXI expression, lasting up to half a year, with no bleeding observed. SRSD107 combines potent and long-lasting effects with good safety and has the potential to become a first-in-class and best-in-class next-generation safer anticoagulant drug.

References:

[1] Lozano R, Naghavi M, Foreman K, et al. Lancet. 2012;380, 2095-1128.